Skip to main content
Clinical Trials/NCT04221737
NCT04221737
Recruiting
Not Applicable

Early Use of Airway Pressure Release Ventilation (APRV) in Patients with Acute Respiratory Distress Syndrome

Hospital Civil de Guadalajara1 site in 1 country150 target enrollmentJuly 15, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Respiratory Distress Syndrome
Sponsor
Hospital Civil de Guadalajara
Enrollment
150
Locations
1
Primary Endpoint
Mechanical ventilation free days
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Airway pressure release ventilation (APRV) is a time-cycled, pressure controlled, intermittent mandatory ventilation mode with extreme inverse I:E ratios. Currently it is considered as a non-conventional ventilatory mode. The investigators aim to compare APRV with conventional mechanical ventilation (MV) in patients with acute respiratory distress syndrome (ARDS).

Detailed Description

Despite the advances in technology and ventilatory modes, mortality of ARDS is still around 40%. Besides prone positioning, the best approach of management is low tidal volume ventilation (LTV). This 'protective ventilation' strategy is not aways effective to improve oxygenation and is associated with an increased requirement of sedation and neuromuscular blocking agents, which increase length of stay and morbidity. APRV is a ventilatory mode based on relatively high and sustained continuous positive pressure, combined with a short phase of release to allow carbon dioxide removal. It also allows unrestricted spontaneous breathing throughout respiration, independent of the ventilator cycle. Providing sustained inflation while limiting duration and frequency of release phase permits limiting volume loss, resulting in progressive and improved alveolar recruitment, an increased alveolar surface area available for gas exchange and improved ventilation-perfusion matching. In this multi-center, prospective, randomized, controlled, open trial, the investigators aim to compare the effects and safety of the early application of time-controlled adaptive method of APRV and conventional ventilation with LTV strategy in patients with severe to moderate ARDS.

Registry
clinicaltrials.gov
Start Date
July 15, 2017
End Date
January 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Miguel Á Ibarra-Estrada

Principal investigator

Hospital Civil de Guadalajara

Eligibility Criteria

Inclusion Criteria

  • Acute respiratory distress syndrome, according to the Berlin definition of ARDS, with adjusted pO2/FiO2 for altitude \<300, and less than 48 h of endotracheal mechanical ventilation

Exclusion Criteria

  • Pregnancy
  • Less than 18 years-old
  • Expected duration of mechanical ventilation less than 48 h
  • Preexisting conditions with an expected 3-month mortality exceeding 50%
  • Concurrent chemotherapy
  • Confirmed intracranial hypertension
  • Catastrophic cranial trauma or neuromuscular disorders that are known to prolong mechanical ventilation
  • Pneumothorax at enrollment (resolved or not)
  • Do-not-resuscitate order

Outcomes

Primary Outcomes

Mechanical ventilation free days

Time Frame: 28 days

Secondary Outcomes

  • All causes mortality(28 days)
  • Tracheostomy rate(28 days)
  • ICU length of stay(28 days)
  • Hospital length of stay(60 days)
  • Average expiratory time(7 days)
  • oxygen partial pressure (pO2)(7 days)
  • Average of prone position sessions(7 days)
  • Mean airway pressure, peak airway pressure, maximum P high(7 days)
  • Rate of neuromuscular blocking agents utilization(7 days)
  • Prone position rate(7 days)
  • Minute ventilation(7 days)
  • pCO2 (carbon dioxide partial pressure)(7 days)
  • Richmond Sedation-Agitation Scale(7 days)
  • Mean arterial pressure(7 days)
  • Maximum dosage of vasopressors requirement(7 days)
  • Average dose of propofol use(7 days)
  • Rate of recruitment maneuvers(7 days)

Study Sites (1)

Loading locations...

Similar Trials